Marker Therapeutics, Inc. (NASDAQ:MRKR) on Tuesday provided an update on the progress and clinical observations from the Phase 1 APOLLO study investigating MT-601, a Multi-Antigen Recognizing (MAR)-T cell product, in patients with lymphoma who have relapsed after anti-CD19 CAR-T cell therapy or for whom anti-CD19 CAR-T cell therapy is not an option.
Last year, Marker Therapeutics restructured its clinical programs and prioritized MT-601.
